Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).

26/05/2019

Abstracts, Publications, Publications Genitourinary

Daniel Vargas Almeida, Cleyton Z. Oliveira, Andrey Soares, RODRIGO COUTINHO MARIANO, Denis L Jardim, Diogo Assed Bastos, Fernando C. Maluf, Gustavo Werutsky, Fernando Sabino M Monteiro, Vinicius Carrera Souza, Guillermo de Velasco, Andre P. Fay, Andre Deeke Sasse, Fabio A. B. Schutz

ASCO 2019; J Clin Oncol 37, 2019 15_suppl.4579, published online only

Full link: https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4579

Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).

Send us a message

Cura Project

Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).

Related Posts

ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy

Prevalence of patients with indication of genetic evaluation for hereditary breast and ovarian syndrome in the Brazilian cohort study – AMAZONA III

Comprehensive genomic profiling of non-small cell lung cancer in Brazil (GBOT 0118/LACOG 0418).

Cross-Cultural Validity Study of a Medical Education Leadership Competencies Instrument in Latin American Physicians: A Multinational Study